Voltage-dependent L-type calcium channel subunit alpha-1 (Cav1) (Cav1)

The Voltage-dependent L-type calcium channel subunit alpha-1 (Cav1) is the primary pore-forming component of L-type voltage-gated calcium channels, which are crucial for mediating calcium entry into cells in response to membrane depolarization [1, 2]. This subunit contains the voltage-sensing domain, the ion conduction pore, and the high-affinity binding sites for clinically significant calcium channel blockers [3, 8]. There are four distinct isoforms: Cav1.1 (skeletal muscle), Cav1.2 (cardiac and smooth muscle), Cav1.3 (neurons and endocrine cells), and Cav1.4 (retina) [1, 7]. These channels are vital for excitation-contraction coupling in muscles, regulating the cardiac action potential, and triggering neurotransmitter and hormone release [1, 13]. Mutations or dysregulation of these subunits are implicated in a variety of diseases, including hypertension, cardiac arrhythmias (such as Brugada and Timothy syndromes), and neuropsychiatric disorders [2, 10, 16]. Pharmacologically, they are the targets of three major classes of drugs—dihydropyridines, phenylalkylamines, and benzothiazepines—which are widely used to manage cardiovascular conditions [7, 11, 12]. These drugs act by binding to the alpha-1 subunit and inhibiting the influx of calcium ions, thereby promoting vasodilation and reducing cardiac contractility [11, 12]. Therapeutic challenges include managing side effects such as peripheral edema and hypotension, as well as the potential for heart failure exacerbation with certain agents [4, 15]. Ongoing research explores the potential of isoform-selective blockers for treating central nervous system disorders like Parkinson's disease and chronic pain [7, 10].

Other names

Voltage-gated L-type calcium channel alpha-1 subunitLTCC alpha-1 subunitCav1.1Cav1.2Cav1.3Cav1.4CACNA1SCACNA1CCACNA1DCACNA1FDihydropyridine receptor

Calcium channel blocker (antagonist)